T3D
MINT IT. PRINT IT.

ASX ANNOUNCEMENT

29 October 2026

Appendix 4C and Quarterly Activities Report

The Board of Directors of 333D Ltd (ASX:T3D or "**Company**") releases its cash flow report (**Appendix 4C**) for the quarter ending 30 September 2026 (**"the quarter"**) and provides an update on activities during the quarter.

QUARTERLY ACTIVITIES REPORT

- **Cash receipts from customers of $639,558**
- **Total cash and digital asset holdings of $523,880**
- **Net operating cash outflow reduced to $62,827 from $250,085 in the June 2026 quarter, an improvement of approximately 75%.**

Principal Activities

333D Limited operates in digital asset creation, management and monetisation, with a focus on healthcare applications including DICOM-based medical imaging. The Company provides software development services, digital asset management services, 3D content creation and AI-enabled file encoding for use across digital platforms and physical outputs such as 3D printing. There was no change in the nature or scale of the Company's activities during the quarter.

Artificial intelligence and product development

The Company continued its strategic focus on applied artificial intelligence and AI-enabled digital asset management. As previously reported, its proprietary clinical software program uses de-identified cone-beam CT imaging data for potential applications in dental and maxillofacial imaging. The June 2026 quarter saw completion of a model training and evaluation milestone. Commencement of pre-deployment optimisation and validation will be the next step before any assessment can be made regarding the commercialisation.

Digital asset management platform

The Company continued providing digital asset management and software development services to customers. Its FY2026 development program was completed in the preceding quarter, and September quarter expenditure was lower, consistent with the anticipated moderation of development spending. The Company continues to focus on its digital asset management strategy and healthcare-related software applications.

Operating and financial review

Cash receipts from customers were $639,558, compared with $820,670 in the June 2026 quarter. Net operating cash outflow improved to $62,827 from $250,085 in June. Total

333D Limited
ABN 24 118 159 881
Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000 Australia

operating payments were $702,386, comprising product manufacturing and operating costs of $387,094, staff costs of $24,078 and administration and corporate costs of $291,214. The comparative June quarter payments were $587,470, $20,578 and $462,707 respectively. Interest received was $1. The reduction in operating cash outflow is consistent with the completion of the FY2026 software development program and lower quarterly expenditure, although the supplied documents do not establish the precise allocation of individual September payments to particular projects.

Bitcoin treasury

The Company continues to hold Bitcoin as a strategic asset under its Bitcoin Treasury Management Policy, as described in the 2026 Annual Report. The September Appendix 4C does not report any cash inflows or outflows from investing activities. The supplied documents do not establish the quantity or market value of Bitcoin at 30 September 2026; accordingly, Bitcoin has not been included in the reported cash balance or funding-runway calculation.

Capital management and funding

Cash and cash equivalents at 30 September 2026 were $249,191, compared with $312,018 at 30 June 2026 in the prior Appendix 4C. The Company reported no financing facilities and no financing cash flows for the quarter. On the basis of the quarter's net operating cash outflow of $62,827, estimated funding available was 3.97 quarters, as disclosed in Item 8 of the Appendix 4C. The Board will continue to monitor cash requirements and discretionary expenditure.

Payments to related parties

Pursuant to ASX *Listing Rule 4.7C.3,* payments to related parties and their associates during the quarter totalled $46,146. This included $2,603 in reimbursements for expenses incurred on behalf of the Company, paid to entities related to Director Dr Nigel Finch, and $3,543 in reimbursements for expenses incurred on behalf of the Company, paid to entities related to Director Mr Richard Petty. The total also included $40,000 in director's fees paid to Mr John Conidi.

Events subsequent to the quarter

Subsequent to the end of the quarter, there were no material events impacting the Company's cash position.

On 28 October 2026 the Company issued its Notice of Annual General Meeting for Friday 27 November 2026 at 11:00 am Melbourne time, to be held virtually.

Use of Funds Statement

The Company confirms that the quarter is not included in a period covered by a "use of funds" statement or expenditure program in a prospectus, PDS or information memorandum previously lodged under *ASX Listing Rule 1.1*.

- END -

The release of this announcement was **authorised by the Board of Directors** of the Company.

About 333D Limited

333D Limited is a digital asset technology company specialising in the creation, management and monetisation of digital content, with a particular focus on healthcare applications. The Company's capabilities include DICOM-based medical imaging, 2D and 3D digital content creation, AI-enabled file encoding, and digital asset management solutions. Its technologies enable digital assets to be used across multiple platforms, including physical outputs such as 3D printing.

To find out more about 333D visit 333D.co

For further enquiries please contact:

John Conidi - Executive Chairman
+61 (0) 411 773 101
john@333d.co

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
333D Limited	
ABN	**Quarter ended ("current quarter")**
26 118 159 881	30 September 2026

Consolidated statement of cash flows		**Current quarter $A**	**Year to date (12 months) $A**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	639,558	639,558
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	-387,094	-387,094
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	-24,078	-24,078
	(f) administration and corporate costs	-291,214	-291,214
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	1
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash used in operating activities**	**-62,827**	**-62,827**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) equity investment	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A	Year to date (12 months) $A
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash used in investing activities**	-	-

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of share capital	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from financing activities**	-	-

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	312,018	312,018
4.2	Net cash from / (used in) operating activities (item 1.9 above)	-62,827	-62,827
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-

Consolidated statement of cash flows		Current quarter $A	Year to date (12 months) $A
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**249,191**	**249,191**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A	Previous quarter $A
5.1	Bank balances	**249,191**	**312,018**
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**249,191**	**312,018**

6.	Payments to related parties of the entity and their associates	Current quarter $A
6.1	Aggregate amount of payments to related parties and their associates included in item 1	46,146
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Payments to related parties during the quarter totalled $46,146. This included $2,603 in reimbursements for expenses incurred on behalf of the Company, paid to entities related to Director Dr Nigel Finch, and $3,543 in reimbursements for expenses incurred on behalf of the Company, paid to entities related to Director Mr Richard Petty. The total also included $40,000 in director's fees paid to Mr John Conidi.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A**	**Amount drawn at quarter end $A**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A**
8.1	Net cash used in operating activities (Item 1.9)	-62,827
8.2	Cash and cash equivalents at quarter end (Item 4.6)	249,191
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	249,191
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**3.97**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **29 October 2026**



Authorised by: **Dr Nigel Finch, Director**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.